Esophagus Adenocarcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: ESP025 MIFTS: 45	Esophagus Adenocarcinoma Categories: Cancer diseases, Gastrointestinal diseases
Genes Tissues Related diseases Publications Pathways Drugs Download Expand all tables

Sources

Aliases & Classifications for Esophagus Adenocarcinoma

MalaCards integrated aliases for Esophagus Adenocarcinoma:

Name: Esophagus Adenocarcinoma ¹² ¹⁵

Adenocarcinoma of Esophagus ¹² ⁴⁴ ⁷³

Oesophageal Adenocarcinoma ¹²

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Gastrointestinal diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:4914

MeSH ⁴⁴ C562730

NCIt ⁵⁰ C4025

SNOMED-CT ⁶⁸ 276803003

UMLS ⁷³ C0279628

Sources

Summaries for Esophagus Adenocarcinoma

Disease Ontology : ¹² An esophageal carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Esophagus Adenocarcinoma, also known as adenocarcinoma of esophagus, is related to adenocarcinoma and squamous cell carcinoma. An important gene associated with Esophagus Adenocarcinoma is HNF1A-AS1 (HNF1A Antisense RNA 1
Long non-coding RNA HNF1A-AS1 regulates proliferation and migration in oesophageal adenocarcinoma cells.
Dysfunction Pattern: Regulation [up-regulated]), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Menthol and Irinotecan have been mentioned in the context of this disorder. Affiliated tissues include testes, liver and colon, and related phenotypes are digestive/alimentary and endocrine/exocrine gland

Sources

Related Diseases for Esophagus Adenocarcinoma

Diseases related to Esophagus Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 127)

#	Related Disease	Score	Top Affiliating Genes
1	adenocarcinoma	30.2	ERBB2 HNF1A-AS1 PIK3CA SMAD4 TP53
2	squamous cell carcinoma	29.7	ERBB2 HNF1A-AS1 PIK3CA SMAD4 TP53
3	esophageal cancer	28.4	ERBB2 MIR21 MYC PIK3CA SMAD4 TP53
4	rare adenocarcinoma of the breast	10.9	PIK3CA TP53
5	adult hepatocellular carcinoma	10.9	PIK3CA TP53
6	gallbladder squamous cell carcinoma	10.9	ERBB2 TP53
7	gastric papillary adenocarcinoma	10.9	ERBB2 TP53
8	malignant spiradenoma	10.9	PIK3CA TP53
9	uterine corpus serous adenocarcinoma	10.9	ERBB2 TP53
10	mutyh-associated polyposis	10.8	SMAD4 TP53
11	vulva basal cell carcinoma	10.8	ERBB2 MYC
12	non-proliferative fibrocystic change of the breast	10.8	ERBB2 TP53
13	pleomorphic adenoma carcinoma	10.8	ERBB2 TP53
14	fallopian tube adenocarcinoma	10.7	ERBB2 TP53
15	uterine body mixed cancer	10.7	ERBB2 TP53
16	glioma susceptibility 1	10.7	ERBB2 TP53
17	anal squamous cell carcinoma	10.7	PIK3CA TP53
18	myasthenic syndrome, congenital, 14	10.7	MYC PIK3CA
19	b cell prolymphocytic leukemia	10.7	MYC TP53
20	oral leukoplakia	10.6	ERBB2 TP53
21	suppression of tumorigenicity 12	10.6	PIK3CA SMAD4 TP53
22	breast squamous cell carcinoma	10.6	ERBB2 PIK3CA TP53
23	bladder squamous cell carcinoma	10.6	ERBB2 PIK3CA TP53
24	ovarian cancer 1	10.6	ERBB2 PIK3CA TP53
25	malignant ovarian surface epithelial-stromal neoplasm	10.6	ERBB2 PIK3CA TP53
26	ovary epithelial cancer	10.6	ERBB2 PIK3CA TP53
27	serous cystadenocarcinoma	10.6	ERBB2 PIK3CA TP53
28	hemimegalencephaly	10.6	MYC PIK3CA
29	estrogen-receptor positive breast cancer	10.6	ERBB2 PIK3CA TP53
30	cystadenocarcinoma	10.6	ERBB2 PIK3CA TP53
31	ovarian serous cystadenocarcinoma	10.6	ERBB2 PIK3CA TP53
32	renal cell carcinoma, papillary, 1	10.6	ERBB2 PIK3CA TP53
33	oral cavity cancer	10.6	ERBB2 PIK3CA TP53
34	megaesophagus	10.6	MYC TP53
35	microglandular adenosis	10.6	ERBB2 TP53
36	uterine corpus cancer	10.6	ERBB2 MYC TP53
37	uterine carcinosarcoma	10.6	ERBB2 PIK3CA TP53
38	bile duct carcinoma	10.6	MYC PIK3CA TP53
39	fallopian tube carcinoma	10.6	ERBB2 MYC TP53
40	cell type cancer	10.5	ERBB2 MYC TP53
41	bladder urothelial carcinoma	10.5	ERBB2 PIK3CA TP53
42	skin melanoma	10.5	ERBB2 PIK3CA TP53
43	esophagus squamous cell carcinoma	10.5	AFAP1-AS1 MIR145
44	adenoid cystic carcinoma	10.5	ERBB2 PIK3CA TP53
45	female reproductive organ cancer	10.3	ERBB2 MYC PIK3CA TP53
46	respiratory system cancer	10.3	ERBB2 MYC PIK3CA TP53
47	breast adenocarcinoma	10.3	ERBB2 MYC PIK3CA TP53
48	suppressor of tumorigenicity 3	10.2	MYC TP53
49	gallbladder cancer	10.2	AFAP1-AS1 ERBB2 PIK3CA TP53
50	cowden disease	10.2	MIR21 PIK3CA SMAD4

Graphical network of the top 20 diseases related to Esophagus Adenocarcinoma:

Sources

Symptoms & Phenotypes for Esophagus Adenocarcinoma

MGI Mouse Phenotypes related to Esophagus Adenocarcinoma:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	digestive/alimentary	MP:0005381	9.43	ATP4A ERBB2 MYC SMAD4 TP53 ATP12A
2	endocrine/exocrine gland	MP:0005379	9.17	ATP4A CDO1 ERBB2 MYC PIK3CA SMAD4

Sources

Drugs & Therapeutics for Esophagus Adenocarcinoma

Drugs for Esophagus Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 181)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Menthol

Approved

Phase 4

2216-51-5

16666

Irinotecan

Approved, Investigational

Phase 4,Phase 2,Phase 1

97682-44-5, 100286-90-6

60838

Oxaliplatin

Approved, Investigational

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

61825-94-3

5310940 9887054 43805 6857599

Fluorouracil

Approved

Phase 4,Phase 3,Phase 2,Phase 1

51-21-8

3385

Levoleucovorin

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1

68538-85-2

leucovorin

Approved, Nutraceutical

Phase 4,Phase 3,Phase 2,Phase 1

58-05-9

143 6006

Folic Acid

Approved, Nutraceutical, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1

59-30-3

6037

Camptothecin

Experimental

Phase 4,Phase 2,Phase 1

7689-03-4

topoisomerase I inhibitors

Phase 4,Phase 2,Phase 1

Micronutrients

Phase 4,Phase 3,Phase 2,Phase 1

Topoisomerase Inhibitors

Phase 4,Phase 3,Phase 2,Phase 1

Trace Elements

Phase 4,Phase 3,Phase 2,Phase 1

Vitamin B Complex

Phase 4,Phase 3,Phase 2,Phase 1

Vitamins

Phase 4,Phase 3,Phase 2,Phase 1

Immunosuppressive Agents

Phase 4,Phase 3,Phase 2,Phase 1

Antidotes

Phase 4,Phase 3,Phase 2,Phase 1

Protective Agents

Phase 4,Phase 3,Phase 2,Phase 1

Liver Extracts

Phase 4,Phase 2,Phase 1

Antimetabolites

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Antimetabolites, Antineoplastic

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Calcium, Dietary

Phase 4,Phase 3,Phase 2,Phase 1

Antineoplastic Agents, Phytogenic

Phase 4,Phase 3,Phase 2,Phase 1

Folate

Nutraceutical

Phase 4,Phase 3,Phase 2,Phase 1

Vitamin B9

Nutraceutical

Phase 4,Phase 3,Phase 2,Phase 1

Capecitabine

Approved, Investigational

Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable

154361-50-9

60953

Cisplatin

Approved

Phase 3,Phase 2,Phase 1

15663-27-1

84093 441203 2767

Carboplatin

Approved

Phase 3,Phase 2,Phase 1

41575-94-4

10339178 498142 38904

Esomeprazole

Approved, Investigational

Phase 3

161796-78-7, 119141-88-7

4594 9579578

Aspirin

Approved, Vet_approved

Phase 3

50-78-2

2244

Paclitaxel

Approved, Vet_approved

Phase 3,Phase 2,Phase 1

33069-62-4

36314

Cetuximab

Approved

Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable

205923-56-4

56842117 2333

Docetaxel

Approved, Investigational

Phase 3,Phase 2,Phase 1

114977-28-5

148124

Epirubicin

Approved

Phase 3,Phase 2,Phase 1

56420-45-2

41867

Gefitinib

Approved, Investigational

Phase 3,Phase 2,Phase 1

184475-35-2

123631

Trioxsalen

Approved

Phase 3,Phase 2

3902-71-4

5585

Tegafur

Approved, Investigational

Phase 3

17902-23-7

5386

Ranitidine

Approved

Phase 3

66357-59-3, 66357-35-5

3001055

Dexamethasone

Approved, Investigational, Vet_approved

Phase 3,Phase 2

50-02-2

5743

Trastuzumab

Approved, Investigational

Phase 3,Phase 2,Phase 1

180288-69-1

9903

Ondansetron

Approved

Phase 3

99614-02-5

4595

Analgesics

Phase 3,Phase 2,Phase 1

Fibrinolytic Agents

Phase 3

Albumin-Bound Paclitaxel

Phase 3,Phase 2,Phase 1

Gastrointestinal Agents

Phase 3

Cyclooxygenase Inhibitors

Phase 3,Phase 2

Analgesics, Non-Narcotic

Phase 3,Phase 2,Phase 1

Antacids

Phase 3

Peripheral Nervous System Agents

Phase 3,Phase 2,Phase 1

Anti-Bacterial Agents

Phase 3,Phase 2,Phase 1,Not Applicable

Antibiotics, Antitubercular

Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 270)

#	Name	Status	NCT ID	Phase	Drugs
1	Endoesophageal Cryotherapy For Ablating Barrett's Esophagus and Early Stage Esophageal Cancer	Unknown status	NCT00628784	Phase 4
2	Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer	Recruiting	NCT02366819	Phase 4	Oxaliplatin;Leucovorin Calcium;Irinotecan Hydrochloride;Fluorouracil
3	Combination Chemotherapy in Treating Patients With Esophageal Cancer	Unknown status	NCT00041262	Phase 3	cisplatin;epirubicin hydrochloride;fluorouracil
4	A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia	Unknown status	NCT00357682	Phase 3	Esomeprazole;Esomeprazole;Aspirin
5	Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus	Unknown status	NCT00002884	Phase 3	chemotherapy;cisplatin;fluorouracil
6	Surgery With or Without Combination Chemotherapy in Treating Patients With Cancer of the Esophagus	Unknown status	NCT00002883	Phase 3	cisplatin;fluorouracil
7	Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal Cancer	Unknown status	NCT00509561	Phase 2, Phase 3	capecitabine;cisplatin
8	Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer	Unknown status	NCT00052910	Phase 3	cisplatin;epirubicin hydrochloride;fluorouracil;leucovorin calcium
9	Confocal Endomicroscopy for Barrett's Esophagus	Completed	NCT00487695	Phase 3
10	Surgery With or Without Radiation Therapy and Chemotherapy in Treating Patients With Esophageal Cancer	Completed	NCT00047112	Phase 3	cisplatin;fluorouracil
11	Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Cancer of the Esophagus	Completed	NCT00002631	Phase 3	chemotherapy;cisplatin;fluorouracil
12	Surgery With or Without Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus	Completed	NCT00003118	Phase 3	cisplatin;fluorouracil
13	Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer	Completed	NCT00020787	Phase 3	cisplatin;fluorouracil
14	Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer	Completed	NCT00861094	Phase 2, Phase 3	cisplatin;5-FU;oxaliplatin;Folinic Acid
15	Gefitinib in Treating Patients With Esophageal Cancer That is Progressing After Chemotherapy	Completed	NCT01243398	Phase 3
16	Symptom Control With or Without Docetaxel in Treating Patients With Relapsed Esophageal Cancer or Stomach Cancer	Completed	NCT00978549	Phase 3	docetaxel;steroid therapy
17	Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus	Recruiting	NCT02509286	Phase 3	5-Fluorouracil;Leucovorin;Oxaliplatin;Docetaxel;Carboplatin;Paclitaxel
18	NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)	Recruiting	NCT01726452	Phase 3	Epirubicin;Cisplatin;5 Flourouracil/ Capecitabine;Paclitaxel;Carboplatin
19	Efficacy and Safety Study of the Combined Modality Therapy in Adenocarcinoma of the Esophago-gastric Junction	Recruiting	NCT01523015	Phase 2, Phase 3
20	STRETTA ,Radio Frequency Ablation (RFA) v/s Sham Therapy for the Treatment of Refractory GERD	Recruiting	NCT02935881	Phase 3
21	A Randomized, Controlled, Multicenter Study to Compare Preoperative Radiochemotherapy With Preoperative Chemotherapy in Patients With Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma	Recruiting	NCT03013010	Phase 3	Tegafur-Gimeracil-Oteracil Potassium;Oxaliplatin
22	Clinical Study of Time Optimizing of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac Cancer	Recruiting	NCT02628665	Phase 3	photosensitizer(photofrin)
23	Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer	Active, not recruiting	NCT01196390	Phase 3	Carboplatin;Paclitaxel
24	Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery	Active, not recruiting	NCT01107639	Phase 3	cisplatin;docetaxel
25	Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma	Unknown status	NCT00964080	Phase 1, Phase 2	MBP-426/Leucovorin/5-FU
26	The Effect of Preoperative Docetaxel, Cisplatin and Capecitabine on Serum RUNX3 Hypermethylation Status in Patients With Gastric and Lower Oesophagus Adenocarcinoma	Unknown status	NCT00674167	Phase 2	Docetaxel;Cisplatin;Capecitabine
27	Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach	Unknown status	NCT00601705	Phase 2	cisplatin;epirubicin hydrochloride;fluorouracil;oxaliplatin
28	Tethered Capsule Endoscope in Screening Participants for Barrett Esophagus	Unknown status	NCT00903136	Phase 1, Phase 2
29	Paclitaxel in Treating Patients With Metastatic, Recurrent, or Unresectable Cancer of the Esophagus	Unknown status	NCT00003326	Phase 2	paclitaxel
30	Combination Chemotherapy Plus Radiation Therapy Followed By Surgery in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer	Unknown status	NCT00006472	Phase 2	carboplatin;fluorouracil;paclitaxel
31	Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Cancer of the Stomach or Esophagus	Unknown status	NCT00005607	Phase 2	FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
32	Liposomal Doxorubicin in Treating Patients With Advanced Stomach Cancer	Unknown status	NCT00004236	Phase 2	pegylated liposomal doxorubicin hydrochloride
33	Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During Surgery	Unknown status	NCT00005876	Phase 2	rubitecan
34	Pre-operative Epirubicin, Cisplatin, and Capecitabine in Patients With Newly Diagnosed Localised Oesophageal Adenocarcinoma	Completed	NCT00220103	Phase 2	epirubicin, capecitabine, cisplatin
35	Phase 2 Study of AMG 386 (20060439) in Combination With Cisplatin & Capecitabine in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma	Completed	NCT00583674	Phase 2	AMG 386 placebo;AMG 386 10mg/kg;AMG 386 3mg/kg;Cisplatin;Capecitabine;Cisplatin;Capecitabine;Cisplatin;Capecitabine
36	Effects Of Lapatinib (GW572016) In Patients With Relapsed Adenocarcinoma Of The Esophagus	Completed	NCT00259987	Phase 2	Lapatinib (GW572016) oral tablets
37	3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction	Completed	NCT00077545	Phase 2	triapine;cisplatin
38	Phase II Study of Irinotecan and Panitumumab	Completed	NCT00836277	Phase 2	Panitumumab;Irinotecan
39	Irinotecan in Treating Patients With Esophageal or Stomach Cancer	Completed	NCT00003748	Phase 2	irinotecan hydrochloride
40	Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia	Completed	NCT00591123	Phase 2	FOLFOX and Erlotinib
41	Irinotecan, Cisplatin, Bevacizumab, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Esophageal Cancer	Completed	NCT00354679	Phase 2	cisplatin;irinotecan hydrochloride
42	Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction	Completed	NCT00891878	Phase 2	capecitabine;sunitinib malate
43	Celecoxib, Paclitaxel, and Carboplatin in Treating Patients With Cancer of the Esophagus	Completed	NCT00066716	Phase 2	carboplatin;celecoxib;paclitaxel
44	Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach	Completed	NCT00020761	Phase 2	irinotecan hydrochloride;paclitaxel
45	Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer	Completed	NCT00985192	Phase 2	everolimus
46	Combination Chemotherapy After Surgery in Treating Patients With Cancer of the Esophagus or Stomach	Completed	NCT00003237	Phase 2	cisplatin;paclitaxel
47	Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction	Completed	NCT00938470	Phase 2	capecitabine;docetaxel;fluorouracil;oxaliplatin
48	Oxaliplatin and Capecitabine in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer	Completed	NCT00040859	Phase 2	capecitabine;oxaliplatin
49	Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer	Completed	NCT00033657	Phase 2	cisplatin;irinotecan hydrochloride;paclitaxel
50	Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer	Completed	NCT00165490	Phase 2	Cetuximab;Cisplatin;Irinotecan

Search NIH Clinical Center for Esophagus Adenocarcinoma

Cochrane evidence based reviews: adenocarcinoma of esophagus

Sources

Genetic Tests for Esophagus Adenocarcinoma

Sources

Anatomical Context for Esophagus Adenocarcinoma

MalaCards organs/tissues related to Esophagus Adenocarcinoma:

⁴¹

Testes, Liver, Colon, Lymph Node, Bone

Sources

Publications for Esophagus Adenocarcinoma

Articles related to Esophagus Adenocarcinoma:

(show all 12)

#	Title	Authors	Year
1	C-Met as a potential novel prognostic marker in squamous cell carcinoma and adenocarcinoma of esophagus: evidence from a meta-analysis. ( 27636117 )	Ren J.L....Wang Y.X.	2017
2	Preliminary evaluation for Bit1 as a potential biomarker for squamous cell carcinoma and adenocarcinoma of esophagus. ( 28488526 )	Chen J....Fan T.	2017
3	The clinical significance of cysteine dioxygenase type 1 methylation in Barrett esophagus adenocarcinoma. ( 28184414 )	Kojima K....Watanabe M.	2017
4	Epigenetic regulation on the gene expression signature in esophagus adenocarcinoma. ( 28049580 )	Xi T....Zhang G.	2016
5	In vivo molecular imaging of HER2 expression in a rat model of Barrett's esophagus adenocarcinoma. ( 24708360 )	Realdon S....Battaglia G.	2014
6	Esophagus adenocarcinoma in a young patient with celiac disease; Is celiac disease a predisposing factor for esophagus adenocarcinoma as well as squamous cell carcinoma? ( 26185881 )	Mahmud B....Mohamadreza Z.K.	2014
7	Increase of epidermal growth factor receptor expression in progression of GERD, Barrett, and adenocarcinoma of esophagus. ( 22875307 )	Pretto G....Meurer L.	2013
8	Comparative evaluation of serum C-reactive protein (CRP) levels in the different histological subtypes of esophageal cancer (squamous cell carcinoma and adenocarcinoma of esophagus). ( 22467322 )	Lukaszewicz-ZajA8c M....Szmitkowski M.	2012
9	Nonsteroidal anti-inflammatory drugs and esophageal inflammation - Barrett's esophagus - adenocarcinoma sequence: a meta-analysis. ( 21166737 )	Wang F....Fu Y.K.	2010
10	Gene expression profiling of esophageal cancer: comparative analysis of Barrett's esophagus, adenocarcinoma, and squamous cell carcinoma. ( 17236199 )	Greenawalt D.M....Phillips W.A.	2007
11	Familiality in Barrett's esophagus, adenocarcinoma of the esophagus, and adenocarcinoma of the gastroesophageal junction. ( 16985029 )	Chak A....Eng C.	2006
12	Meningeal carcinomatosis in patient with esophagus adenocarcinoma. ( 9105327 )	Girola S.S....Mazzone A.	1997

Sources

Genes for Esophagus Adenocarcinoma

Genes related to Esophagus Adenocarcinoma (0 elite genes):

(show all 14)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	HNF1A-AS1	HNF1A Antisense RNA 1 Long non-coding RNA HNF1A-AS1 regulates proliferation and migration in oesophageal adenocarcinoma cells. Dysfunction Pattern: Regulation [up-regulated]	RNA Gene	154.52	Experimental evidence: Regulation ³⁹ DISEASES inferred ¹⁵	24000294
2	AFAP1-AS1	AFAP1 Antisense RNA 1 Using quantitative reverse-transcription PCR,we assessed expression levels of AFAP1-AS1 in 20 matched pairs of human EAC and adjacent NE as well as in 12 matched pairs of human benign BE and adjacent NE. AFAP1-AS1 expression was elevated relative to NE in the majority of EACs (15/20) and BEs (11/12). These data suggest that AFAP1-AS1 expression is up-regulated in both EAC cell lineand primary EAC tissues,consistent with the DNA hypomethylation observed in these same samples. BE and EAC exhibit reduced methylation that includes non-coding regions. Methylation of the long noncoding RNA AFAP1-AS1 is reduced in BE and EAC,and its expression inhibits cancer-related biologic functions of EAC cells. Dysfunction Pattern: Regulation [up-regulated]	RNA Gene	150	Experimental evidence: Regulation ³⁹	23333711
3	MIR215	MicroRNA 215 Expression of miR-215 was low in normal squamous epithelium and high in Barrett's oesophagus. However, its expression was significantly lower in oesophageal adenocarcinoma than in Barrett's epithelium. Recent studies have demonstrated that miR-215 is induced by p53 in response to genotoxic stress, and that miR-215 induction can result in cell cycle arrest. These studies also demonstrated that miR-215 levels were high in normal colonic epithelium, but decreased in colonic cancer. This raises the possibility that miR-215 has a tumour suppressor role in Barrett's oesophagus epithelium.	RNA Gene	50	Unspecified ⁴⁷	20301167
4	MIR145	MicroRNA 145 miR-145 was highly expressed in columnar epithelial tissues from the upper gastrointestinal tract but miR-145 had lower levels of expression in oesophageal adenocarcinoma than in Barrett's oesophagus and gastric epithelium. miR-145 would seem worthy of investigation as markers of neoplastic progression.	RNA Gene	50	Unspecified ⁴⁷	20301167
5	MIR143	MicroRNA 143 miR-143 was highly expressed in columnar epithelial tissues from the upper gastrointestinal tract but miR-143 had lower levels of expression in oesophageal adenocarcinoma than in Barrett's oesophagus and gastric epithelium. miR-143 would seem worthy of investigation as markers of neoplastic progression.	RNA Gene	50	Unspecified ⁴⁷	20301167
6	MIR21	MicroRNA 21 Expression of miR-21 was significantly higher in all types of columnar epithelium (intestinal metaplasia, gastric epithelium, oesophageal adenocarcinoma) than in normal squamous epithelium. Columnar tissues had higher levels of miR-21 expression than squamous oesophageal epithelium.	RNA Gene	50	Unspecified ⁴⁷	20301167
7	TP53	Tumor Protein P53	Protein Coding	24.29	DISEASES inferred ¹⁵ GeneCards inferred via : Variants (show sections)
8	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	22.56	DISEASES inferred ¹⁵ GeneCards inferred via : Variants (show sections)
9	MYC	MYC Proto-Oncogene, BHLH Transcription Factor	Protein Coding	21.77	DISEASES inferred ¹⁵ GeneCards inferred via : Variants (show sections)
10	SMAD4	SMAD Family Member 4	Protein Coding	17.51	GeneCards inferred via : Variants (show sections)
11	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	17.51	GeneCards inferred via : Variants (show sections)
12	ATP12A	ATPase H+/K+ Transporting Non-Gastric Alpha2 Subunit	Protein Coding	16.6	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
13	ATP4A	ATPase H+/K+ Transporting Subunit Alpha	Protein Coding	16.6	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
14	CDO1	Cysteine Dioxygenase Type 1	Protein Coding	16.55	GeneCards inferred via : Publications (show sections)

Sources

Variations for Esophagus Adenocarcinoma

Sources

Expression for Esophagus Adenocarcinoma

Search GEO for disease gene expression data for Esophagus Adenocarcinoma.

Sources

Pathways for Esophagus Adenocarcinoma

Pathways related to Esophagus Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 33)

#	Super pathways	Score	Top Affiliating Genes
1	Endometrial cancer ³⁷ Show member pathways Acute myeloid leukemia ³⁷ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁶ Chronic myeloid leukemia ³⁷ Colorectal cancer ³⁷ Pancreatic cancer ³⁷ Prostate cancer ³⁷ Signal transduction PTEN pathway ²² Thyroid cancer ³⁷	12.7	ERBB2 MYC PIK3CA SMAD4 TP53
2	Pathways in cancer ³⁷	12.64	ERBB2 MYC PIK3CA SMAD4 TP53
3	Gastric cancer ³⁷ Show member pathways Breast cancer ³⁷ Hepatocellular carcinoma ³⁷	12.54	ERBB2 MYC PIK3CA SMAD4 TP53
4	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ¹ Immune response IL-10 signaling pathway ²² Rac1/Pak1/p38/MMP-2 pathway ¹	12.44	ERBB2 MYC PIK3CA TP53
5	Kaposi's sarcoma-associated herpesvirus infection ³⁷ Show member pathways Hepatitis B ³⁷	12.42	MYC PIK3CA SMAD4 TP53
6	ErbB signaling pathway ¹ ³⁷ Show member pathways EGFR Inhibitor Pathway, Pharmacodynamics ⁶¹ Renal cell carcinoma ³⁷ TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer ¹	12.33	ERBB2 MYC PIK3CA TP53
7	HTLV-I infection ³⁷	12.27	MYC PIK3CA SMAD4 TP53
8	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ¹	12.25	ERBB2 MYC PIK3CA SMAD4 TP53
9	Cellular senescence (KEGG) ³⁷	12.04	MYC PIK3CA TP53
10	Integrated Breast Cancer Pathway ¹	12.02	MYC SMAD4 TP53
11	Proteoglycans in cancer ³⁷	12.02	ERBB2 MIR21 MYC PIK3CA TP53
12	Development EGFR signaling via small GTPases ²² Show member pathways Development EGFR signaling via PIP3 ²² Development PDGF signaling via MAPK cascades ²² PDGF Pathway ¹	12.01	ERBB2 MYC PIK3CA
13	AKT Signaling Pathway ⁶⁷	11.97	ERBB2 MYC PIK3CA TP53
14	Signaling pathways regulating pluripotency of stem cells ³⁷	11.96	MYC PIK3CA SMAD4
15	TGF-beta Signaling Pathway (WikiPathways) ¹	11.93	MYC SMAD4 TP53
16	Development IGF-1 receptor signaling ²² Show member pathways Signal transduction AKT signaling ²²	11.9	MYC PIK3CA TP53
17	MAPK Pathway ⁷² Show member pathways Toll-like Receptor Pathway ⁷²	11.89	ERBB2 PIK3CA TP53
18	Thyroid hormone signaling pathway ³⁷	11.85	MYC PIK3CA TP53
19	Immune response IL-2 activation and signaling pathway ²² Show member pathways Immune response IL-3 activation and signaling pathway ²²	11.82	MYC PIK3CA SMAD4
20	Small cell lung cancer ³⁷	11.74	MYC PIK3CA TP53
21	MicroRNAs in cancer ³⁷	11.7	ERBB2 MIR143 MIR145 MIR21 MIR215 MYC
22	Validated targets of C-MYC transcriptional activation ¹	11.66	MYC SMAD4 TP53
23	Bladder cancer ³⁷ ¹	11.59	ERBB2 MYC TP53
24	Platinum drug resistance ³⁷	11.58	ERBB2 PIK3CA TP53
25	Validated targets of C-MYC transcriptional repression ¹	11.46	ERBB2 MYC SMAD4
26	DNA Damage Response (only ATM dependent) ¹	11.41	ERBB2 MYC PIK3CA SMAD4 TP53
27	Pathways Affected in Adenoid Cystic Carcinoma ¹	11.38	ERBB2 MYC PIK3CA TP53
28	Hepatitis C and Hepatocellular Carcinoma ¹	11.34	MYC SMAD4 TP53
29	miRNAs involved in DNA damage response ¹	11.31	MIR145 MYC TP53
30	Central carbon metabolism in cancer ³⁷	11.27	ERBB2 MYC PIK3CA TP53
31	LKB1 signaling events ¹	11.2	MYC SMAD4 TP53
32	Inhibition of Ribosome Biogenesis by p14(ARF) ⁶⁴	10.99	MYC TP53
33	TP53 Network ¹ Show member pathways Activation, translocation and oligomerization of BAX ⁶⁶	10.98	MYC TP53

Sources

GO Terms for Esophagus Adenocarcinoma

Biological processes related to Esophagus Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 15)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of gene expression	GO:0010628	9.84	ERBB2 MIR21 MYC TP53
2	cell proliferation	GO:0008283	9.81	ERBB2 MYC SMAD4 TP53
3	negative regulation of angiogenesis	GO:0016525	9.65	MIR143 MIR145 MIR21
4	positive regulation of vascular associated smooth muscle cell migration	GO:1904754	9.55	MIR143 MIR21
5	regulation of smooth muscle contraction	GO:0006940	9.52	MIR143 MIR145
6	cellular sodium ion homeostasis	GO:0006883	9.49	ATP12A ATP4A
7	cellular potassium ion homeostasis	GO:0030007	9.46	ATP12A ATP4A
8	positive regulation of protein kinase B signaling	GO:0051897	9.46	ERBB2 MIR143 MIR21 PIK3CA
9	sodium ion export across plasma membrane	GO:0036376	9.43	ATP12A ATP4A
10	establishment or maintenance of transmembrane electrochemical gradient	GO:0010248	9.4	ATP12A ATP4A
11	angiotensin-activated signaling pathway	GO:0038166	9.37	MIR143 MIR145
12	aorta smooth muscle tissue morphogenesis	GO:0060414	9.32	MIR143 MIR145
13	regulation of phenotypic switching	GO:1900239	9.26	MIR143 MIR145
14	establishment or maintenance of cell type involved in phenotypic switching	GO:0044663	8.96	MIR143 MIR145
15	negative regulation of cardiac muscle hypertrophy	GO:0010614	8.8	MIR145 MIR21 SMAD4

Molecular functions related to Esophagus Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	sodium:potassium-exchanging ATPase activity	GO:0005391	8.96	ATP12A ATP4A
2	potassium:proton exchanging ATPase activity	GO:0008900	8.62	ATP12A ATP4A

Sources

Sources for Esophagus Adenocarcinoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia